Revenue

9 Months Ended

Sep. 30, 2022

Disaggregation Of Revenue [Abstract]

Revenue

11. Revenue  

The following table provides information about disaggregated revenue by product mix and service (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Product revenue:
ANNOVERA	$	10,415	$	11,807	$	37,196	$	30,112
IMVEXXY		6,947		8,016		20,583		24,866
BIJUVA		2,663		3,298		7,877		7,899
Prescription vitamin		892		1,335		2,671		4,162
Product revenue, net		20,917		24,456		68,327		67,039
License and service		-		950		484		1,234
Total revenue, net	$	20,917	$	25,406	$	68,811	$	68,273

We have entered into a license and supply agreement (the “Knight License Agreement”), with Knight Therapeutics, Inc. (“Knight”) pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. We also have entered into a licensing and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) pursuant to which we granted Theramex an exclusive license to commercialize IMVEXXY and BIJUVA for human use outside of the U.S., except for Canada and Israel.

We recorded BIJUVA sales through the Theramex License Agreement of $0.4 million and $1.4 million for the three and nine months ended September 30, 2022, respectively, and $0.7 million for the three and nine months ended September 30, 2021. For the three and nine months ended three and nine months ended September 30, 2022 and 2021, no BIJUVA sales have been made through the Knight License Agreement.